ArticleEuropean journal of medical research2025
Adverse effects of linezolid in the treatment of drug-resistant tuberculosis combined with diabetic peripheral neuropathy.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Comparative Evaluation of the Therapeutic Effects of Adenosine Triphosphate, Coenzyme Q10, Pyridoxine, and Thiamine Pyrophosphate in a Linezolid-Induced Peripheral Neuropathic Pain Model in Rats.Pharmaceuticals (Basel, Switzerland) · 2026Article
- From linezolid to contezolid: a strategy for safe continuation of therapy in complex tuberculosis.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis aimed to observe the adverse effects of linezolid on nerve conduction velocity in patients with drug-resistant tuberculosis combined with diabetic peripheral neuropathy.
methodsPatients hospitalized in our hospital from March 2018 to March 2022 were divided into the drug-resistant tuberculosis (DRTB) group, type 2 diabetes peripheral neuropathy (DPN) group, and type 2 diabetic peripheral neuropathy combined with drug-resistant tuberculosis (DM-DRTB) group. The drug-resistant TB treatment regimen used linezolid with antituberculous drugs. Neurophysiological examinations were performed on the patients before and 2 months after treatment, the conduction velocities of the superficial peroneal nerve and peroneal nerve of the lower limbs of the three groups were recorded, and the conduction velocities of the deep peroneal nerve, superficial peroneal nerve, common peroneal nerve, tibial nerve, and femoral nerve of the lower limb motor nerves of the three groups were compared and statistically analyzed.
resultsAfter 2 months of linezolid treatment, the sensory nerve conduction velocities of the superficial peroneal nerve and sural nerve of the lower limb in the DRTB group and the DM-DRTB group significantly decreased, and the difference was statistically significant (p < 0.05). There was no significant decrease in the motor nerve conduction velocities of the deep peroneal nerve, superficial peroneal nerve, common peroneal nerve, tibial nerve, or femoral nerve of the lower limb in the DRTB and the DM-DRTB groups, and the differences were not statistically significant (p > 0.05).
conclusionLinezolid can slow lower limb sensory nerve conduction velocity in patients with DRTB and DM-DRTB; however, the effect on lower limb motor nerves was not significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.